Beam Therapeutics Inc. (BEAM) Stock

Beam Therapeutics Inc. (BEAM) is a Healthcare stock trading at $28.39 (as of 2026-08-20), with a market capitalization of $2.93B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Beam Therapeutics Inc. is developing precision genetic medicines and related therapies for patients in the United States, with programs that include candidates for sickle cell disease, beta thalassemia, relapsed/refractory T-cell acute lymphoblastic leukemia, and liver and other disorders such as Glycogen Storage Disease Type Ia and alpha-1 antitrypsin deficiency.

Understand Beam Therapeutics Inc.: how it makes money

Beam Therapeutics is a biotechnology company developing precision genetic medicines, including BEAM-101 and BEAM-102 for sickle cell disease, and BEAM-201 and BEAM-301 for other serious diseases, and it generates money mainly from license and collaboration arrangements while advancing clinical trials.

Because Beam is still developing its genetic medicines, its near term revenue is largely driven by license and collaboration revenue, while the operating trajectory depends on progressing patients through clinical trials for BEAM-101 and other programs.

Business quality (Weak): Segment disclosure is not cleanly reconcilable with the stated total revenue for the quarter based on the provided facts, but the clinical trial operating metrics and the quarter operating loss context are clear.

Bull case

  • Clinical execution underway for BEAM-101: In the BEACON Phase 1/2 trial of BEAM-101, Beam reports patients enrolled and patients dosed, indicating active treatment of study participants.
  • Some non product revenue exists: The company has license and collaboration revenue in the provided quarterly facts, suggesting partnering activity contributes to revenue in the near term.

Bear case

  • Profits are not evident in the latest quarter: For the quarter ended 2026-03-31, Beam reports an operating margin of -337.8 percent, indicating substantial operating losses.
  • Revenue is small relative to development stage: The only segment style revenue fact provided is license and collaboration revenue, while the company is still in clinical development across multiple candidates, which typically keeps revenues limited until commercialization.
  • Execution risk remains tied to trial progress: Key operating measures provided relate to patient dosing and trial cohorts, so outcomes and continued enrollment or dosing activity can materially affect future progress.
Valuation — source: SEC EDGAR (first-party)
Price$28.39
Market Cap$2.93B
Price / Book2.75
Price / Sales39.81
FCF Yield-25.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$139.74M
Net Margin-57.2%
Revenue Growth (YoY)120.0%
EPS Growth (YoY)-82.3%
FCF Growth (YoY)1.1%
Financial Health — source: SEC EDGAR
Altman Z-Score5.78 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($296.74M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJohn Evans
Employees393
CountryUS
IPO Date2020-02-06

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Iovance Biotherapeutics, Inc. (IOVA)
  • Relay Therapeutics, Inc. (RLAY)
  • Tarsus Pharmaceuticals, Inc. (TARS)
  • Kodiak Sciences Inc. (KOD)
  • BioCryst Pharmaceuticals, Inc. (BCRX)
  • ADMA Biologics, Inc. (ADMA)
  • Hemab Therapeutics Holdings, Inc. (COAG)
  • Vericel Corporation (VCEL)
BEAM earnings history · BEAM institutional & insider holders · BEAM KPIs & operating metrics · BEAM financials · BEAM investor presentations & press releases · BEAM SEC filings · BEAM peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.